Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 12/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.51 |
| ▸ | DRD2 | P14416 | 2/20 | 0.50 |
| ▸ | DRD4 | P21917 | 2/20 | 0.50 |
| ▸ | DRD3 | P35462 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3559925 | 0.90 | HTR1A (0.72) | HTR1AKDM4EALDH1A1 | |
| SCHEMBL6638117 | 0.84 | HTR1A (0.53) | HTR1AKDM4EALDH1A1GAASIGMAR1 | |
| SCHEMBL6637087 | 0.84 | NCF1 (0.53) | HTR1AKDM4EALDH1A1GAASIGMAR1 | |
| SCHEMBL14266792 | 0.82 | USP2 (0.53) | HTR1AKDM4EALDH1A1DRD2DRD4 | |
| SCHEMBL6637537 | 0.82 | HTR1A (0.51) | HTR1AALDH1A1DRD2DRD4DRD3 | |
| SCHEMBL6640750 | 0.82 | HTR1A (0.49) | HTR1AKDM4EALDH1A1GAASIGMAR1 | |
| SCHEMBL6637562 | 0.80 | DRD2 (0.61) | HTR1AALDH1A1DRD2DRD4DRD3 | |
| SCHEMBL6663048 | 0.80 | HTR3E (0.47) | HTR1AALDH1A1DRD2DRD4DRD3 | |
| SCHEMBL6663053 | 0.79 | HTR3E (0.47) | HTR1AKDM4EALDH1A1DRD2DRD4 | |
| SCHEMBL3555203 | 0.78 | HTR2A (0.62) | HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7671056-B2 | Piperazine-piperidine antagonists and agonists of the 5-HT1A receptor | WYETH LLC (US) | 2010-03-02 | — | — | US | disclosed |
| US-7671056-B2 | Piperazine-piperidine antagonists and agonists of the 5-HT1A receptor | WYETH LLC (US) | 2010-03-02 | — | — | US | disclosed |
| EP-2035384-A2 | PROCESS FOR SYNTHESIZING PIPERAZINE-PIPERIDINE COMPOUNDS | Wyeth a Corporation of the State of Delaware (US) | 2009-03-18 | — | — | EP | disclosed |
| US-20080058523-A1 | Processes for synthesizing piperazine-piperidine compounds | WYETH | 2008-03-06 | — | — | US | disclosed |
| US-20080058523-A1 | Processes for synthesizing piperazine-piperidine compounds | WYETH | 2008-03-06 | — | — | US | disclosed |
| US-20080058523-A1 | Processes for synthesizing piperazine-piperidine compounds | WYETH | 2008-03-06 | — | — | US | disclosed |
| WO-2007146072-A2 | PROCESS FOR SYNTHESIZING PIPERAZINE-PIPERIDINE COMPOUNDS | WYETH (US) | 2007-12-21 | — | — | WO | disclosed |
| US-20070027160-A1 | 5-fluoro-8-(4-(4-(6-methoxyquinolin-8-yl)piperazin-1-yl)piperidin-1-yl)quinoline; central nervous system disorders, such as cognition disorders, anxiety disorders, depression and sexual dysfunction | WYETH (US) | 2007-02-01 | — | — | US | disclosed |
| US-20070027160-A1 | 5-fluoro-8-(4-(4-(6-methoxyquinolin-8-yl)piperazin-1-yl)piperidin-1-yl)quinoline; central nervous system disorders, such as cognition disorders, anxiety disorders, depression and sexual dysfunction | WYETH (US) | 2007-02-01 | — | — | US | disclosed |
| EP-1147083-B1 | ARYLPIPERAZINYL-CYCLOHEXYL INDOLE DERIVATIVES FOR THE TREATMENT OF DEPRESSION | WYETH CORP (US) | 2004-06-16 | — | — | EP | disclosed |
| US-6465482-B2 | ANTIDEPRESSANTS; ANXIOLYTIC AGENTS; SEROTONIN-AFFECTED NERVOUS SYSTEM DISORDERS; ACTING AT THE 5-HT1A AUTORECEPTORS CONCOMMITANTLY WITH 5-HT TRANSPORTERS; ANTISEROTONIN AGENTS; SEROTONIN REUPTAKE INHIBITORS; HT3 RECEPTOR ANTAGONISTS | WYETH | 2002-10-15 | — | — | US | disclosed |
| US-20020045628-A1 | Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-04-18 | — | — | US | disclosed |
| US-6313126-B1 | FOR THRERAPY OF DISORDERS ASSOCIATED WITH DYSFUNCTION IN SEROTONERGIC NEUROTRANSMISSION, INCLUDING DEPRESSION AND ANXIETY | AMERICAN HOME PRODUCTS CORP | 2001-11-06 | — | — | US | disclosed |
| EP-1147083-A1 | ARYLPIPERAZINYL-CYCLOHEXYL INDOLE DERIVATIVES FOR THE TREATMENT OF DEPRESSION | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-10-24 | — | — | EP | disclosed |
| WO-2000040554-A1 | ARYLPIPERAZINYL-CYCLOHEXYL INDOLE DERIVATIVES FOR THE TREATMENT OF DEPRESSION | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058523-A1 | Processes for synthesizing piperazine-piperidine compounds | HTR5A, HTR2A, HTR1A | HTR1A 3/4885KDM4E 2874/4885ALDH1A1 281/4885 |
| US-20020045628-A1 | Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression | HTR2C, TPH1, TPH2 | HTR1A 9/4885KDM4E 1582/4885ALDH1A1 3101/4885 |
| US-20070027160-A1 | 5-fluoro-8-(4-(4-(6-methoxyquinolin-8-yl)piperazin-1-yl)piperidin-1-yl)quinoline; central nervous system disorders, such as cognition disorders, anxiety disorders, depression and sexual dysfunction | HTR5A, HTR2C, HTR1D | HTR1A 4/4885KDM4E 907/4885ALDH1A1 752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.